The Hong Kong stock IPO market remains the same in October, and the HKEx will usher in five major hot new stocks. According to market news, pharmaceutical stocks Xiansheng Pharmaceutical, Pharmaceutical Ming Giant Nuo, Rongchang Biology, property stocks Hejing leisurely living, Shimao Services will start their initial public offering in mid-late October.

Star contestants come one after another, the IPO period is likely to crash, how can all the big meat be eaten? Don't worry, put away the new tactics of the old driver.

Taking Futu Securities, a well-known domestic brokerage, as an example, it has provided sufficient financing quotas for these five hot new shares:

It is worth noting that, according to the latest news, Ant Group will issue shares from October 27 to 30, which will mean that Yao Ming Junuo and Rongchang will collide with the strongest IPO in history.The new period of Hejing leisurely living and Shimao service does not conflict with Ant Group.

In order to make sure you don't get lost, the following article will take an inventory of the basic overview and investment highlights of each new stock for your reference and help you to select the potential stocks with the best quality. Come and have a look with the old driver.

Combine the scenery with leisurely life.

IPO time on the Internet:October 19-22

Amount of funds raised:About $400 million to $500 million

Hejing leisurely living is a property management company spun off by HK.1813. In 2019, the company ranked seventh among the property management companies providing commercial operation services in China and fifth in the Greater Bay area.

Investment highlight

1. Golden track. The periodicity of the property management industry is weak, and the stock and incremental market is huge. The size of the property management market is expected to exceed 1.2 trillion yuan in 2022.

2. Market position. In 2020, in terms of comprehensive strength, the company ranked 17th among the top 100 property service enterprises in China.

3. Parent group support. Hop King Pacific is a leading real estate developer in the mainland and brings solid support to the company's business.

4. Growth speed. The company's financial data have grown rapidly in the past three years, with net profit rising from 40 million yuan in 2017 to 190 million yuan in 2019, with a compound annual growth rate of 104.8 percent.

Shimao service

IPO time on the Internet:October 20-23

Amount of funds raised:About $500 million to $600 million

Valuation:HK $148.2-40.47 billion

Shimao Service, a subsidiary of Shimao Group, is a leading provider of integrated property management and community life services in China. In 2019, according to the comprehensive strength, the company was ranked 12th among the "Top 100 property Service Enterprises in China" by the Central Index Institute.

Investment highlight

1. Golden track. The periodicity of the property management industry is weak, and the stock and incremental market is huge. The size of the property management market is expected to exceed 1.2 trillion yuan in 2022.

2. Financial growth. The company's net profit increased sharply from 110 million yuan in 2017 to 380 million yuan in 2019, with a compound annual growth rate of 88 per cent.

3. Capital favor. Top investment institution Sequoia Capital and Internet giant Tencent hold 5.3 per cent and 4.7 per cent respectively.

4. Big-name sponsor. China International Capital Corporation and Morgan Stanley are co-sponsors.

Yao Ming Ju Nuo

IPO time on the Internet:October 22-28

Amount of funds raised:About $200 million to $300 million

Valuation:Approximately $548 million (pre-IPO)

Yao Ming Juno is a biopharmaceutical company specializing in cellular immunotherapy, and it is also the first company in China to obtain the clinical approval of CAR-T cell therapy product IND with CD19 as the target. Founded in April 2016, it was jointly established by Wuxi Apptec and American Giant Nuo Company.

Investment highlight

1. The market potential is huge.. The global CAR-T treatment market is expected to grow from about $734 million in 2019 to $4.7 billion in 2024, with a compound annual growth rate of 45.3 per cent.

2. Rich R & D pipelines. With the second domestic listed CAR-T therapy, in the leading position of the track.

3. Star capital Yunji Inc. Juno, the leading player in the US CAR-T field, holds 26.09%, Wuxi Apptec 14.20% and Temasek 8.42%.

4. Big-name sponsor. Goldman Sachs Group and UBS jointly sponsor.

Rongchang Bio-B

IPO time on the Internet:October 26-29

Valuation:About 1.37 billion dollars

Founded in 2008, Rongchang Biology is an innovative biopharmaceutical company dedicated to the development and commercialization of pioneering and best-in-class biopharmaceuticals for the treatment of autoimmune (systemic lupus erythematosus SLE), oncology and ophthalmology diseases.

Investment highlight

1. Market prospect. ADC is a new hot spot in antibody drug research and development, and it is a blue ocean field in China. At present, it has only been approved for indications or created more than 3 billion of the domestic market.

2. The core products have great potential.. Tetacil, the core product, is the only innovative biomedicine for optic neuromyelitis spectrum disease in the stage of III clinical development in China, with an annual compound growth rate of 29.3% in the target market.

3. Commercialization process. The core product, Tetasip, is expected to be conditionally licensed and sold in the fourth quarter of 2020.

4. Big-name sponsor.Morgan Stanley, Huatai International and JPMorgan Chase & Co are recommended jointly.

Xiansheng Pharmaceutical Industry

IPO time:October 13-16

Time to market:October twenty _ third

Amount of funds raised:About 500 million dollars

Market capitalization:HK $31.529 billion-35.698 billion

Xiansheng Pharmaceutical Co., Ltd., founded in 1995, is a new pharmaceutical group integrating drug research and development, production and sales. At present, it is mainly engaged in generic medicine business, focusing on oncology, central nervous system and autoimmunity.

In 2007, Xiansheng Pharmaceutical listed on the New York Stock Exchange as the first Chinese biological and chemical pharmaceutical company in 2007, with a market capitalization of more than $1 billion, and then privatized and delisted from the US stock market in December 2013.

Investment highlight

1. Popular track. The three major areas of oncology, central nervous system and autoimmunity are the high-growth track, accounting for 24.7% of the entire Chinese pharmaceutical market in terms of drug sales revenue in 2019.

2. Industry leader. It has been ranked among the "Top Ten innovative Pharmaceutical Enterprises in China" and "Top 100 Pharmaceutical Industry in China" for many years, and 8 products have been included in the national health insurance drug list.

3. Profit improvement. In 2019, the company's net profit exceeded 1 billion yuan, with a compound annual growth rate of 69.2% in the past three years, and the gross profit margin remained stable at more than 80%.

4. Big-name sponsor. Morgan Stanley and China International Capital Corporation are jointly recommended.

From a fundamental point of view, the texture of the above-mentioned new stocks are all good.

From the perspective of market heat, property stocks and biomedical stocks are often popular in the new stock market and are highly sought after by investors.

Since the beginning of this year, a total of 13 biomedical stocks have landed on the Hong Kong Stock Exchange, and 12 have risen on the first day, with an average increase of 41% on the first day. Among them, Okangwei Bio-B, Peijia Medical-B and Kang Bio closed up 152%, 68% and 50% respectively, and their first-hand income could reach HK $11170, HK $10440 and HK $8120, far exceeding the average share price performance of the market.

The property management stock has always maintained a strong trend, of the seven property companies listed so far this year, only one broke on the first day of listing, the others are ushered in a "good start", and most of them have a good performance after listing.

With a balance of less than 100 days in 2020, the Hong Kong stock IPO market continues to be hot. In addition to these five hot new stocks, the HKEx will also welcome big players such as Ant Group and Blue Moon. I hope all of you who are enthusiastic about playing new can eat big meat in 2020!